Sanofi will be closing the doors to a research facility in the biotech hub of Cambridge, UK, a move that will impact around 90 people. The site previously belonged to antibody developer Kymab, a biotech that Sanofi acquired in 2021 for $1.1 billion upfront. The deal centered around an anti-OX40L monoclonal antibody designed to improve outcomes in patients with atopic dermatitis. Source: Fierce Biotech 13/3/2024